RTS,S/AS02A malaria vaccine-induced IgG responses equally recognize native-like fucosylated and non-fucosylated Plasmodium falciparum circumsporozoite proteins-Reference-Cited by-同舟云学术

RTS,S/AS02A malaria vaccine-induced IgG responses equally recognize native-like fucosylated and non-fucosylated Plasmodium falciparum circumsporozoite proteins

Published:2023-01-10 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Dobaño Carlota¹^ORCID,Jairoce Chenjerai²,Macià Dídac¹,Torres-Yaguana Jorge¹,Mayer Leonie¹,Vidal Marta³,Santano Rebeca¹,Hurtado-Guerrero Ramón⁴,Reiter Karine⁵,Narum David⁶^ORCID,Lopez-Gutierrez Borja⁷^ORCID,Hamerly Timothy⁷^ORCID,Sacarlal Jahit⁸,Aguilar Ruth³,Dinglasan Rhoel⁷^ORCID,Moncunill Gemma⁹^ORCID,Izquierdo Luis¹⁰^ORCID

Affiliation:

1. Barcelona Institute for Global Health (ISGlobal)

2. Manhiça Health Research Centre

3. Barcelona Institute for Global Health

4. University of Zaragoza: Universidad de Zaragoza, Institute of Biocomputation and Physics of complex systems

5. Laboratory of Malaria Immunology and Vaccinology, NIAID/NIH

6. National Institutes of Health

7. University of Florida

8. Centro de Investigação em Saúde de Manhiça (CISM)

9. ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona

10. ISGlobal

Abstract

AbstractThe RTS,S/AS02A malaria vaccine is based on thePlasmodium falciparumcircumsporozoite protein (PfCSP), which is O-fucosylated on the sporozoite surface. We determined whether RTS,S/AS02A-induced IgGs recognise vaccine-like non-fucosylated PfCSP better than native-like fucosylated PfCSP. Similar to previous vaccine trials, RTS,S/AS02A vaccination induced high anti-CSP IgG levels associated with malaria protection. IgG recognition of non-fucosylated and fucosylated PfCSP was equivalent, suggesting that PfCSP fucosylation does not affect antibody recognition.

Publisher

Research Square Platform LLC

Reference18 articles.

1. WHO. World Malaria Report 2021. Word Malaria report Geneva: World Health Organization. (2021). Licence: CC (2021).

2. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children;ST A;The New England journal of medicine,2011

3. RTS, S. C. T. P. A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. New England Journal of Medicine vol. 367 2284–2295 Preprint at https://doi.org/10.1056/nejmoa1208394 (2012).

4. Implications of Plasmodium glycosylation on vaccine efficacy and design;Goddard-Borger ED;Future microbiology,2018

5. Toward a first landmark on the Malaria Vaccine Technology Roadmap;Kaslow DC;Vaccine,2015